IL15 and melanoma: We have previously shown in a phase I trial in dogs that inhaled recombinant human (rh) IL-15 is associated with anti-tumor activity in dogs with metastatic OSA and melanoma, observing an objective response rate of 11% and a clinical benefit rate of 39% among 18 evaluable dogs (19).